Xceleron has announced that, following signature of a Master Services Agreement with Sanofi-Aventis Deutschland GmbH, a number of studies are underway to assess the human metabolism of novel compounds in early clinical development. This work utilises Xceleron’s ultra-sensitive Accelerator Mass Spectrometry (AMS) technology platform.
This latest deal adds to Xceleron’s growing client list of major organisations – including 15 of the world’s top 20 pharma companies.
Xceleron’s foundation in 1997 was supported by GSK, Novartis, Pfizer and Janssen (now Johnson & Johnson). Notably after many years of working with Xceleron to explore the potential of AMS, GSK now have 2 AMS machines of their own - focused specifically on similar kinds of metabolite profiling studies to those now being undertaken by Sanofi-Aventis.